Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls Publisher Pubmed



Farrokhi M1, 2 ; Etemadifar M1, 2 ; Jafary Alavi MS3 ; Zarkeshesfahani SH3 ; Behjati M4 ; Rezaei A5, 6 ; Amanibeni A1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Multiple Sclerosis and Neuroimmunology Research Center, Isfahan, Iran
  3. 3. Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
  4. 4. Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, United States
  6. 6. Department of Neuroscience, Brown University, Providence, RI, United States

Source: Immunological Investigations Published:2015


Abstract

Background: Aberrant immune responses are evident in the pathogenesis of multiple sclerosis (MS) and it has been proposed that the spectrum of cytokines influence disease outcomes. Leptin and lipopolysaccharide (LPS) of Gram-negative bacteria are both potent cellular stimulators for production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α). The aim of this study was to compare the TNF-α production by peripheral blood monocytes from MS patients with healthy controls.Methods: Peripheral blood samples were stimulated with LPS or leptin. After blocking the Golgi apparatus, intracellular cytokine production was assessed using a monoclonal antibody against human TNF-α by the flow cytometry technique. Moreover, plasma level measurement of cytokines was performed using enzyme-linked immunosorbent assay (ELISA).Results: Intracellular levels of TNF-α were 16.80 ± 8.21 and 16.52 ± 8.23in MS patients and healthy controls which showed no statistically significant difference between them (p = 0.850). Leptin-stimulated and LPS-stimulated TNF-α production showed no significant difference between MS patients and the control group (p = 0.263 and p = 0.191, respectively). However, after treatment with leptin, a weak significant difference was shown between cases and control group (p = 0.049). There were significant differences between cases and controls regarding serum levels of IL-6 and Toll-like receptor-4 (TLR-4) before and after stimulation with leptin and LPS, separately (p < 0.05).Conclusion: Taken together, we cannot definitely conclude that TNF-α does not play an important role in pathogenesis of MS. However, other characteristics of monocyte activation such as IL-6 or TLRs can elucidate implication of peripheral blood monocytes in MS pathogenesis. © 2015 Taylor and Francis Group, LLC.
Other Related Docs
16. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
19. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
29. Pemphigus Vulgaris in a Patient With Multiple Sclerosis: A Case Report With 7 Years of Follow Up, Journal of Research in Dental and Maxillofacial Sciences (2023)
44. Serum Homocysteine Level in Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2005)